キクチ　ケン   Kikuchi Ken   菊池　賢    所属   医学部 医学科（東京女子医科大学病院）    職種   教授
論文種別	原著
言語種別	英語
査読の有無	査読なし
表題	The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.
掲載誌名	正式名：Transplant immunology 略　 称：Transpl Immunol ISSNコード：18785492/09663274
掲載区分	国外
巻・号・頁	77,pp.101777
著者・共著者	ARIMURA Ken, TAGAYA Etsuko, KIKUCHI Ken, MITSUDA Toshihiro, EBIHARA Fumiya, MARUYAMA Takumi, HAMADA Yukihiro, UNAGAMI Kohei, KANAZAWA Taichi, SEKIGUCHI Haruki, SHIMAMOTO Ken, ISHIDA Hideki, EGAWA Hiroto, TANAKA Junji, KAWANA Masatoshi
発行年月	2023/04
概要	INTRODUCTION:Transplant recipients (TRs) are at high risk for severe coronavirus disease 2019 (COVID-19). Neutralizing monoclonal antibodies (mAbs) are used for treating mild-to-moderate COVID-19. However, reports comparing the efficacy of COVID-19 treatment without/with mAbs in TRs are limited. We assessed the efficacy of casirivimab/imdevimab against mild-to-moderate COVID-19 in TRs.METHODS:Forty-one patients were retrospectively evaluated. The duration until defervescence, oxygen (O2) requirement ≥5 L, and neutralizing antibody levels were compared in TRs with COVID-19 without/with casirivimab/imdevimab.RESULTS:Casirivimab/imdevimab was correlated with shorter duration until defervescence and non-requirement of O2 ≥ 5 L in TRs with COVID-19 [mean: without/with: 6 vs. 2; P = 0.0002, hazard ratio (HR) = 0.3333, 95% confidence interval (CI) = 0.1763-0.6301; 15 vs. 8; P < 0.0001, HR = 0.5333, 95% CI = 0.2878-0.9883; P = 0.0377, HR = 0.1502, 95% CI = 0.02511-0.8980]. Casirivimab/imdevimab was associated with early defervescence after adjusting for sex and age (P = 0.013, HR = 0.412, 95% CI = 0.205-0.826). The antibody levels between patients without/with casirivimab/imdevimab on the day of hospitalization were not significantly different (P = 0.1055), including 13 TRs with vaccination. Antibody levels were higher in patients with casirivimab/imdevimab at 3-5 days after hospitalization than in those without, at 7-9 days after hospitalization (P < 0.0001, mean, without/with: 414.9/40000 AU/mL).CONCLUSION:Casirivimab/imdevimab was effective and increased the neutralizing antibody in TRs with mild-to-moderate COVID-19, it may contribute toward preventing the progression.
DOI	10.1016/j.trim.2022.101777
PMID	36584927